Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant adenovirus-interferon/Syn3

A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFNα2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFNα2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:rAd-IFN/Syn3
recombinant adenovirus-interferon with Syn3
Foreign brand name:Instiladrin
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search